We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

16 hedge funds and large institutions have $5.36M invested in Tempest Therapeutics in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.05% less ownership

Funds ownership: 2.32% → 2.27% (-0.05%)

20% less capital invested

Capital invested by funds: $6.67M → $5.36M (-$1.31M)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$95.4K
2
TRCT
Tower Research Capital (TRC)
New York
+$3.71K
3
Franklin Resources
Franklin Resources
California
+$771
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$178
5
Wells Fargo
Wells Fargo
California
+$59

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$132K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$17.1K
3
Millennium Management
Millennium Management
New York
-$6.2K
4
UBS Group
UBS Group
Switzerland
-$4.83K
5
Bank of America
Bank of America
North Carolina
-$4.57K
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$1.79M – – –
RSCM
2
Rock Springs Capital Management
Maryland
$1.43M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$1.13M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$419K -$17.1K -578 -3%
Fidelity International
5
Fidelity International
Bermuda
$225K – – –
BlackRock
6
BlackRock
New York
$144K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$117K +$95.4K +3,215 +163%
Renaissance Technologies
8
Renaissance Technologies
New York
$47K -$682 -23 -1%
Franklin Resources
9
Franklin Resources
California
$20K +$771 +26 +3%
Millennium Management
10
Millennium Management
New York
$19K -$6.2K -209 -20%
TRCT
11
Tower Research Capital (TRC)
New York
$8K +$3.71K +125 +53%
UBS Group
12
UBS Group
Switzerland
$5K -$4.83K -163 -42%
Morgan Stanley
13
Morgan Stanley
New York
$1K – – –
BNP Paribas Financial Markets
14
BNP Paribas Financial Markets
France
$127 +$178 +6 New
IC
15
Ikarian Capital
Texas
– -$132K -4,756 Closed
Bank of America
16
Bank of America
North Carolina
– -$4.57K -154 -99%
Wells Fargo
17
Wells Fargo
California
– +$59 +2 +67%

TPST Hedge Fund Activity: Q3 2022 in Review

16 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2022, worth a combined $5.36M — down 20% from $6.67M a quarter earlier.

Fund positioning in TPST was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 5 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $95.4K. The largest seller was Ikarian Capital, exiting entirely with an estimated $132K sold.

  • 16 institutional investors held Tempest Therapeutics (TPST) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $5.36M of Tempest Therapeutics stock for Q3 2022, down 20% quarter-over-quarter.
  • 1 fund opened new Tempest Therapeutics positions in Q3 2022 and 1 closed out, a net change of 0 holders.
  • The largest Tempest Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $95.4K added.
  • The largest Tempest Therapeutics seller in Q3 2022 was Ikarian Capital, an estimated $132K sold.

Based on aggregated 13F filings for Q3 2022.